ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,781 to 3,800 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Standard Breast Irradiation vs Breast Radiation Plus Regional Radiation: serious adverse events1 of 927

3 of 893

-0.2 points

-0.9 to 0.3

1,820NCT00005957

Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer

Standard of Care Plus (SCP) vs Collaborative Care/Stepped Care (CC/SC): deaths from any cause21 of 927

34 of 893

-1.5 points

-3.2 to 0.0

1,820NCT02674464

Reducing Inequities in Care of Hypertension, Lifestyle Improvement for Everyone (RICH LIFE Project)

AAC Only vs AAC + TMCP: Number of Patients Contacted for Quitline Enrollment273 of 1,393

59 of 426

5.7 points

1.6 to 9.4

1,819NCT02764385

Using a Teachable Moment Communication Process to Improve Outcomes of Quitline Referrals

EVO100 Gel vs Placebo Gel: Percentage of Study Successes in the EVO100 and Placebo Treatment Groups684 of 906

696 of 913

-0.7 points

-4.7 to 3.2

1,819NCT04553068

Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection

All TNFI Initiators Monotherapy vs Tofacitinib Initiators Monotherapy: Number of Participants With mACR20 at 6 Months for Tofacitinib Monotherapy vs TNFi Monotherapy394 of 1,683

28 of 135

2.7 points

-5.2 to 9.0

1,818NCT05576051

To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.

Nirsevimab vs No Intervention: Number of Participants With Recurrent Wheeze (for United Kingdom Reconsented Participants)101 of 928

96 of 888

0.1 points

-2.8 to 2.9

1,816NCT05437510

Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life

Olaparib vs Placebo: serious adverse events79 of 911

79 of 904

-0.1 points

-2.7 to 2.5

1,815NCT02032823

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

Non-Opioid vs Opioid: Number of Participants Receiving Rescue Medication26 of 909

54 of 906

-3.1 points

-5.1 to -1.2

1,815NCT04452344

Opioid Analgesic Reduction Study

Non-Opioid vs Opioid: serious adverse events1 of 909

2 of 906

-0.1 points

-0.7 to 0.4

1,815NCT04452344

Opioid Analgesic Reduction Study

High Tranfusion Threshold vs Low Transfusion Threshold: serious adverse events206 of 908

197 of 906

0.9 points

-2.9 to 4.8

1,814NCT01702805

Transfusion of Prematures Trial

Dalteparin vs Placebo: Number of Participants With Minor Bleeding187 of 895

110 of 918

8.9 points

5.5 to 12.3

1,813NCT00786474

Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)

Dalteparin vs Placebo: Major Bleeding29 of 895

12 of 918

1.9 points

0.6 to 3.4

1,813NCT00786474

Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)

Absorb BVS vs XIENCE: Landmark Analysis on TLF and Components38 of 1,202

16 of 610

0.5 points

-1.3 to 2.1

1,812NCT01751906

ABSORB III Randomized Controlled Trial (RCT)

RV Pacing vs Biventricular Pacing: Chronic Atrial Fibrillation (Defined as Presence of Atrial Fibrillation in Two Subsequent ECG´s/Visits)91 of 908

76 of 902

1.6 points

-1.1 to 4.3

1,810NCT00187278

Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization

RV Pacing vs Biventricular Pacing: Total Mortality307 of 908

305 of 902

-0.0 points

-4.4 to 4.3

1,810NCT00187278

Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization

RV Pacing vs Biventricular Pacing: Adverse Events Related to Left Ventricular Lead1 of 908

38 of 902

-4.1 points

-5.6 to -2.9

1,810NCT00187278

Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization

RV Pacing vs Biventricular Pacing: Death Due to Cardiovascular Causes106 of 908

107 of 902

-0.2 points

-3.2 to 2.8

1,810NCT00187278

Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization

RV Pacing vs Biventricular Pacing: Death or Heart Failure Hospitalization346 of 908

363 of 902

-2.1 points

-6.6 to 2.4

1,810NCT00187278

Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization

RV Pacing vs Biventricular Pacing: deaths from any cause307 of 908

305 of 902

-0.0 points

-4.4 to 4.3

1,810NCT00187278

Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization

RV Pacing vs Biventricular Pacing: serious adverse events641 of 908

698 of 902

-6.8 points

-10.8 to -2.7

1,810NCT00187278

Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=190"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=190

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00005957-sae",
        "title": "Standard Breast Irradiation vs Breast Radiation Plus Regional Radiation: serious adverse events",
        "summary": "1 of 927 against 3 of 893; risk difference -0.2 points, 95% interval -0.9 to 0.3; NCT00005957, Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer",
        "record": "/library/comparisons/NCT00005957-sae",
        "nct_id": "NCT00005957",
        "kind": "serious-adverse-events",
        "participants": 1820,
        "risk_difference": {
          "value": -0.002280713834438054,
          "lower": -0.008812239734750147,
          "upper": 0.0031941949991347893
        },
        "group_1": "1 of 927",
        "group_2": "3 of 893",
        "difference": "-0.2 points",
        "interval": "-0.9 to 0.3",
        "trial_title": "Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer"
      },
      {
        "id": "NCT02674464-deaths",
        "title": "Standard of Care Plus (SCP) vs Collaborative Care/Stepped Care (CC/SC): deaths from any cause",
        "summary": "21 of 927 against 34 of 893; risk difference -1.5 points, 95% interval -3.2 to 0.0; NCT02674464, Reducing Inequities in Care of Hypertension, Lifestyle Improvement for Everyone (RICH LIFE Project)",
        "record": "/library/comparisons/NCT02674464-deaths",
        "nct_id": "NCT02674464",
        "kind": "deaths",
        "participants": 1820,
        "risk_difference": {
          "value": -0.015420186491844151,
          "lower": -0.0320202154543638,
          "upper": 0.0004577838311548531
        },
        "group_1": "21 of 927",
        "group_2": "34 of 893",
        "difference": "-1.5 points",
        "interval": "-3.2 to 0.0",
        "trial_title": "Reducing Inequities in Care of Hypertension, Lifestyle Improvement for Everyone (RICH LIFE Project)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=191",
  "request_id": "TPVFMvB42G7tRUJE"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?